Collaborative programs

Garvan drives a number of collaborative programs with scientific and medical institutes globally
The Clinical Immunogenomics Research Consortium Australasia uses genomics to inform diagnosis and treatment for complex immunological diseases.
Australian Parkinson’s Mission
A five-year, international collaborative program for Parkinson’s disease, integrating clinical trials with potentially transformative genomic analysis and biomarkers research.
Hope Research
A radical program to understand autoimmune disease. Our researchers think there may be a common cause to type 1 diabetes, multiple sclerosis, lupus and rheumatoid arthritis.
ProMis (Prostate Cancer Metastasis) brings together researchers from different backgrounds to collectively understand and tackle the mechanisms responsible for metastatic prostate cancer.
Genomics of Type 1 Diabetes
A collaborative program to study the genes and factors that lead to complications in type 1 Diabetes, such as kidney failure or hypoglycaemic unawareness.
The Garvan-Weizmann partnership
The partnership between the Garvan Institute of Medical Research and the Weizmann Institute of Science is a collaborative international endeavour that harnesses the synergistic strengths of two world-class research institutes.
Exceptional Responders Program
A collaborative study of those who have exceptional responses to cancer treatment — and using this knowledge to help others with the disease.
Genomic Cancer Medicine Program
The AGCMP is dedicated to using genomics to improve the understanding, early detection, prevention and management of cancer.
Brain Cancer Seq
A collaboration between the Garvan Institute of Medical Research and the Charlie Teo Foundation, providing an unprecedented look into brain cancer.